436 related articles for article (PubMed ID: 24889480)
21. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR; Whittaker S
Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
[TBL] [Abstract][Full Text] [Related]
22. Mycosis fungoides and the Sézary syndrome.
Foss F
Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
[TBL] [Abstract][Full Text] [Related]
23. A rare presentation of erythrodermic mycosis fungoides.
Goyal T; Varshney A
Cutis; 2012 May; 89(5):229-32, 236. PubMed ID: 22768436
[TBL] [Abstract][Full Text] [Related]
24. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
Reddy SA
Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
[TBL] [Abstract][Full Text] [Related]
25. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
Hoppe RT; Wood GS; Abel EA
Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
[TBL] [Abstract][Full Text] [Related]
26. Cyclosporine in the treatment of cutaneous T cell lymphoma.
Street ML; Muller SA; Pittelkow MR
J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1084-9. PubMed ID: 2273106
[TBL] [Abstract][Full Text] [Related]
27. Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy.
Klein RS; Dunlop JD; Samimi SS; Morrissey KA; Evans KG; Gardner JM; Introcaso CE; Vittorio CC; Rook AH; Micaily B; Kim EJ
J Am Acad Dermatol; 2013 Jun; 68(6):972-7. PubMed ID: 23415461
[TBL] [Abstract][Full Text] [Related]
28. [Therapy of malignant lymphoma of the skin].
Sterry W
Dtsch Med Wochenschr; 1988 Feb; 113(6):221-3. PubMed ID: 3276495
[No Abstract] [Full Text] [Related]
29. The molecular pathogenesis of mycosis fungoides and Sézary syndrome.
Döbbeling U
G Ital Dermatol Venereol; 2008 Dec; 143(6):385-94. PubMed ID: 19169211
[TBL] [Abstract][Full Text] [Related]
30. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
31. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
32. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
33. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
36. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.
Yamashita T; Abbade LP; Marques ME; Marques SA
An Bras Dermatol; 2012; 87(6):817-28; quiz 829-30. PubMed ID: 23197199
[TBL] [Abstract][Full Text] [Related]
37. Disappearance of seborrheic keratoses following treatment with methotrexate.
Seyfer SJ; Duvic M
Cutis; 2013 Jul; 92(1):E2-3. PubMed ID: 23961531
[No Abstract] [Full Text] [Related]
38. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
[TBL] [Abstract][Full Text] [Related]
39. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
Furue M; Kadono T
J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
[TBL] [Abstract][Full Text] [Related]
40. Mycosis fungoides and Sézary syndrome.
Hwang ST; Janik JE; Jaffe ES; Wilson WH
Lancet; 2008 Mar; 371(9616):945-57. PubMed ID: 18342689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
